---
title: "BUZZ-BMO lifts AbbVie PT, sees continued strength in immunology drugs"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292492921.md"
datetime: "2026-07-13T13:04:44.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292492921.md)
  - [en](https://longbridge.com/en/news/292492921.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292492921.md)
---

# BUZZ-BMO lifts AbbVie PT, sees continued strength in immunology drugs

BMO Capital Markets raises its price target on AbbVie (ABBV.N) to $300 from $258, maintains its “outperform” rating

Says continued strength in blockbuster immunology drugs Skyrizi and Rinvoq supports its positive view on the drugmaker despite emerging competition from newly launched therapies

Expects Skyrizi sales to remain resilient, citing its efficacy, psoriatic arthritis approval and less-frequent dosing schedule

The new price target represents a ~21% upside to the stock’s last close

For aesthetics business, BMO says macroeconomic pressures and shifting consumer preferences toward a more natural look continue to weigh on dermal filler brand Juvederm

More upbeat on Botox Cosmetic, citing seasonal demand, higher tax refunds and increased use of GLP-1 weight-loss medicines

Expects AbbVie to report Q2 revenue of $16.83 billion, slightly above consensus, but earnings per share of $3.59, below consensus due to a recently disclosed R&D-related charge

Twenty-six of 33 brokerages rate the stock “buy” or higher, 7 “hold”; their median PT is $263 - LSEG data

As of last close, stock up 8.6% YTD

### Related Stocks

- [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md)
- [BMO.US](https://longbridge.com/en/quote/BMO.US.md)

## Related News & Research

- [Genmab, AbbVie clarify primary endpoints in Phase 3 EPCORE DLBCL-1 trial](https://longbridge.com/en/news/293659753.md)
- [AbbVie Touts Record Sales and Pipeline Momentum at Annual Meeting](https://longbridge.com/en/news/285815191.md)
- [GLP-1 drugs could reduce long-term sick leave: Study](https://longbridge.com/en/news/293847884.md)
- [Helus Pharma Fast-Tracks Phase 3 Enrollment for MDD Drug HLP003](https://longbridge.com/en/news/293390329.md)
- [FDA advisers recommend against the first unapproved peptide on second day of meeting](https://longbridge.com/en/news/293780907.md)